Galway and the west received a massive jobs boost yesterday morning when medtech giant Aerogen announced the creation of more than 700 jobs in the city and in Shannon.
The transformational scaling and investment plan, will result in the creation of 725 new jobs in Ireland over the next 10 years.
The Aerogen Group is headquartered in Dangan, Galway and the new Irish jobs will be across R&D, manufacturing, science and engineering and located there and at its two manufacturing sites in Parkmore, Galway and in Shannon.
The implementation of the transformational scaling plan will enable Aerogen to create up to 725 highly skilled jobs in the West by 2035 increasing its global workforce to over 2,000 of which over 1,100 will be based in Ireland.
With over 25 years of experience, 300 international patents and over 200 clinical papers, Aerogen technology has been used to treat over 25 million patients in emergency departments, adult and paediatric ICUs, general wards and ambulance services in 75 countries worldwide.
Aerogen offers a safe and powerful drug delivery device for the treatment of critical respiratory illness and other non-respiratory illnesses and is the leading manufacturer of high performance, single-use, respiratory nebulisers in the world.
It is Ireland’s largest indigenous medtech company and Enterprise Ireland’s largest client company in the sector, having firmly established itself as the world leader in acute care aerosol drug delivery.
This announcement was made in conjunction with Enterprise Ireland’s End of Year Results for 2024, which confirms that total employment at companies supported by the agency increased to a record 234,454 last year, with 15,741 new jobs created. 64% of the new jobs created in these client companies were located outside the Dublin region with all nine regions recording jobs growth.
Minister for Enterprise, Trade and Employment Peter Burke was on site in Galway to preside over Aerogen’s growth announcement and deliver Enterprise Ireland’s results.
“The government through Enterprise Ireland is targeting ambitious scaling of Irish multinationals that will help drive the Irish economy and our competitive advantage forward. Aerogen’s announcement today is evidence of that Irish multinational ambition in action, and we are delighted to support them on their patient-focused mission," he said.
Commenting on the positive employment growth figures recorded by companies supported by Enterprise Ireland, Minister Burke said it is hugely positive to see Enterprise Ireland-supported companies recording job growth for the fourth year in a row.
"2024 was a challenging year for some sectors of exporting Irish businesses with high interest rates and international instability impacting business performance, so to record significant employment growth is even more impressive. Today’s announcement that Aerogen will implement an ambitious scaling plan, creating high quality jobs here in the west of Ireland is very welcome and demonstrates the continued success of Irish companies’ performance in export markets. The government stands firm in our commitment to Irish companies competing and growing on a global scale.”
Aerogen - Transformational Scaling Plan
As part of the ten-year scaling and investment plan, Aerogen aims to accelerate its existing device technology through new product innovation and leveraging of global opportunities.
Simultaneously it will build its emerging biopharmaceutics business with a major breakthrough in treating premature newborns with Infant Respiratory Stress Syndrome.
High quality R&D is crucial to its goal to become a global leader in pulmonary medicine and biopharmaceutics delivery, combined with a true commitment to improving patient care through cutting-edge technologies.
Aerogen has been growing at over 20% per annum for the last decade with annual revenues now over €150 million and has contributed €130 million to local Irish businesses in the time. Over the next five years Aerogen expects to contribute a further €250 million in income and corporation taxes, directly benefiting the Irish economy.
John Power, CEO and Founder of Aerogen welcomed the announcement and support.
"Enterprise Ireland have been a superb partner in supporting this journey on which we just reached the pivotal milestone of having treated our 25th millionth patient, and we will continue to innovate across the respiratory journey for patients from our HQ here in Galway," he said. Speaking to media, he said that he is confident that Galway will maintain the ambition to encourage the development of medtech and will be able to provide the quality of employee needed to fill the new posts to drive Aerogen's expansion.
The expansion is supported by Enterprise Ireland, who welcome the creation of high value jobs and the strengthening of Ireland’s position in the global value chain of medical technology and manufacturing.
Leo Clancy, CEO, Enterprise Ireland said ambitious companies like Aerogen embody Enterprise Ireland’s vision – that Irish owned, globally focused companies will be the primary driver of our economy. Aerogen has the potential and ambition to achieve billions in revenue, joining the ranks of industry-leading Irish multinationals.
"Mario Draghi’s 2024 report on European competitiveness highlighted the importance of investment in R&D to create a vibrant European industrial base. Aerogen is a wonderful exemplar of what Ireland and Europe can achieve if our scaling companies engage our great talent base in product innovation at scale in key markets,” he continued.
Headquartered in Galway, Aerogen is the world leader in acute care aerosol drug delivery. With over 25 years of experience, 300 international patents and 200+ clinical papers, Aerogen technology has been used to treat over 25 million patients in over 75 countries worldwide.?
Based on a pioneering vibrating mesh technology, the Aerogen Solo has become the global gold standard for respiratory patient care across the hospital from the emergency department to intensive care. The company continues to leverage their expertise, research, technologies, and partnerships to make the greatest possible difference to patient outcomes.
